Literature DB >> 14616525

Intraportal transplantation of allogenic pancreatic islets encapsulated in barium alginate beads in diabetic rats.

Stephan Schneider1, Marc-Alexander von Mach, Oliver Kraus, Peter Kann, Peter Johannes Feilen.   

Abstract

The survival of microencapsulated islets transplanted into the unmodified peritoneal cavity is limited, even if capsular overgrowth is restricted to a minimum, due to an insufficient oxygen supply to the islets. Therefore, research efforts should focus on finding or creating a transplantation site, which permits a closer contact between the encapsulated islets and the blood. For this reason, the liver could be an interesting candidate. The aim of the present study was to test the hypothesis that the intraportal transplantation of allogenic islets encapsulated in small-sized barium alginate beads is safe and succeeds to induce normoglycemia in diabetic rats. The intraportal transplantation of 1,500 islets encapsulated in barium alginate beads leads within 10 h and up to 24 h to blood sugar concentrations below 40 mg/dL, most likely due to an acute cell lysis of the graft. Afterwards, the reappearance of the diabetic state could be detected in these animals. Most likely these findings are induced by a sudden hypoxia to the islets. We believe that the occlusion of small- and medium-sized portal venules by the alginate beads is responsible for this effect. Therefore, in forthcoming studies, barium alginate beads, with a diameter below 350 micro m, stabilized with medical approved additives should be used.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14616525     DOI: 10.1046/j.1525-1594.2003.07159.x

Source DB:  PubMed          Journal:  Artif Organs        ISSN: 0160-564X            Impact factor:   3.094


  7 in total

Review 1.  Challenges and emerging technologies in the immunoisolation of cells and tissues.

Authors:  John T Wilson; Elliot L Chaikof
Journal:  Adv Drug Deliv Rev       Date:  2007-10-11       Impact factor: 15.470

2.  Encapsulated islets transplantation: Past, present and future.

Authors:  Naoaki Sakata; Shoichiro Sumi; Gumpei Yoshimatsu; Masafumi Goto; Shinichi Egawa; Michiaki Unno
Journal:  World J Gastrointest Pathophysiol       Date:  2012-02-15

Review 3.  Nanotechnology in cell replacement therapies for type 1 diabetes.

Authors:  Alexander U Ernst; Daniel T Bowers; Long-Hai Wang; Kaavian Shariati; Mitchell D Plesser; Natalie K Brown; Tigran Mehrabyan; Minglin Ma
Journal:  Adv Drug Deliv Rev       Date:  2019-02-02       Impact factor: 15.470

4.  Limitations in the Use of Fluorescein Diacetate/Propidium Iodide (FDA/PI) and Cell Permeable Nucleic Acid Stains for Viability Measurements of Isolated Islets of Langerhans.

Authors:  Vinc Boyd; Olivia Maria Cholewa; Klearchos K Papas
Journal:  Curr Trends Biotechnol Pharm       Date:  2008-03

5.  Microencapsulating and Banking Living Cells for Cell-Based Medicine.

Authors:  Wujie Zhang; Xiaoming He
Journal:  J Healthc Eng       Date:  2011-12       Impact factor: 2.682

6.  Thrombosis and inflammation in intraportal islet transplantation: a review of pathophysiology and emerging therapeutics.

Authors:  John T Wilson; Elliot L Chaikof
Journal:  J Diabetes Sci Technol       Date:  2008-09

7.  Layer-by-layer assembly of a conformal nanothin PEG coating for intraportal islet transplantation.

Authors:  John T Wilson; Wanxing Cui; Elliot L Chaikof
Journal:  Nano Lett       Date:  2008-06-12       Impact factor: 11.189

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.